EnGene Therapeutics (ENGN) Stock Gets Fair Value Boost After Analyst Views On LEGEND Data
Leerink Partners Upgrades enGene Therapeutics to Outperform, Announces $5 Price Target
Update: enGene Shares Rise After Updating Pivotal Bladder Cancer Data
Piper Sandler Upgrades enGene Therapeutics to Overweight, Maintains Price Target to $4
Wells Fargo Upgrades enGene Therapeutics to Overweight, Raises Price Target to $6
enGene Therapeutics Inc. (ENGN) Discusses Updated LEGEND Data and Regulatory Path for Detalimogene Transcript
enGene Therapeutics Inc. (ENGN) Discusses Updated LEGEND Data and Regulatory Path for Detalimogene - Slideshow
enGene to Initiate a BLA Submission for Detalimogene by Year End and Reports New Data from LEGEND Trial Pivotal Cohort 1 in BCG-Unresponsive NMIBC
enGene Appoints Key Executives in Anticipation of Upcoming Regulatory and Commercial Milestones
enGene to Participate in Upcoming Investor Conferences
enGene Therapeutics Inc. (ENGN) Discusses Preclinical Data and Clinical Case Studies on Incorporating Surfactant Bladder Rinse into Treatment - Slideshow
enGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update Path
enGene Therapeutics Inc. (ENGN) Discusses Preclinical Data and Clinical Case Studies on Incorporating Surfactant Bladder Rinse into Treatment Transcript
enGene to Host KOL Webinar on October 15, 2026
enGene Therapeutics Inc. (ENGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
enGene Therapeutics: Slashing Cash Burn To Bring Their Asset To The Market
Citizens Reiterates Market Perform on enGene Therapeuticsto Market Perform
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
enGene Holdings Q3 EPS $(0.47) Misses $(0.43) Estimate
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.